Abstract
Hypertrophic cardiomyopathy is a cardiac disorder of unknown aetiology which is characterised by hypertrophy of a non-dilated left ventricle. The course of hypertrophic cardiomyopathy may be relatively benign, but the risk of sudden death due to ventricular arrhythmias is an important clinical problem. Those patients at greatest risk of sudden death appear to be those with the combination of diagnosis in childhood, a family history of hypertrophic cardiomyopathy and sudden death, and syncopal episodes. The treatment of hypertrophic cardiomyopathy-associated ventricular tachycardia with 'conventional' antiarrhythmic agents (disopyramide, quinidine, mexiletine) has seldom been successful. However, treatment of this arrhythmia with amiodarone in well-matched but non-parallel groups of patients has resulted in suppression of arrhythmia and improved survival compared with that seen with 'conventional' antiarrhythmic agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
